{
    "clinical_study": {
        "@rank": "13396", 
        "arm_group": [
            {
                "arm_group_label": "SBRT + Cetuximab + Docetaxel followed by Cetuximab + Docetaxel", 
                "arm_group_type": "Other", 
                "description": "Previously Treated With Cetuximab - Group A No Previous Cetuximab - Group C"
            }, 
            {
                "arm_group_label": "SBRT + Cetuximab followed by Cetuximab", 
                "arm_group_type": "Other", 
                "description": "Previously Treated with Cetuximab - Group B No Previous Cetuximab - Group D"
            }
        ], 
        "brief_summary": {
            "textblock": "Compare the overall survival of patients with the addition of docetaxel to the overall\n      survival of patients treated with SBRT and cetuximab alone.  In addition, we will determine\n      the difference in progression free survival (PFS), the rate of local recurrence (LR) and of\n      distant metastases (DM) across the SBRT and cetuximab + docetaxel arm and the arm receiving\n      SBRT and cetuximab alone.  To better resolve the impact of the experimental treatment on\n      PFS, LR, and DM, patients will be stratified by the presence/absence of prior cetuximab\n      treatment and then randomized  to either the control arm  (cetuximab and SBRT only) or the\n      experimental arm (cetuximab, SBRT, and docetaxel)."
        }, 
        "brief_title": "Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN)", 
        "condition": [
            "Recurrent", 
            "Head and Neck Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Squamous Cell", 
                "Head and Neck Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically-proven recurrent squamous cell carcinoma of the head and neck (SCCHN),\n             who has received prior radiotherapy with or without chemotherapy. New primary is\n             allowed if location is in a previously irradiated field.  Biopsy is recommended for\n             each recurrence but is not mandated per study.  This will be at the discretion of the\n             principal investigator.\n\n          -  Prior radiation dose of at least 50 Gy.\n\n          -  Disease confined to locoregional site and can be encompassed in a stereotactic body\n             radiosurgery \"portal\"\n\n          -  Tumor must be deemed to be inoperable or unresectable either by clinical or\n             radiographic criteria.  These criteria include encasement of great vessels, vertebral\n             invasion or undue peri-operative risk.\n\n          -  Prior surgery for recurrent or new SCCHN is allowed in previously irradiated\n             patients.  A minimum of 4 weeks should elapse between any surgery and treatment on\n             study. However, high-risk pathologic features should be present, such as positive\n             margins, positive lymphadenopathy, perineural or angiolymphatic invasion.\n\n          -  Karnofsky performance status > 60 (ECOG 0-1)\n\n          -  Prior treatment with an EGFR Inhibitor is allowed if it was a part of prior curative\n             therapy and was completed at least 30 days prior to commencement of study therapy\n\n          -  Any number of prior chemotherapy regimens are allowed\n\n          -  Measurable disease on imaging studies (MRI, CT, PET-CT or physical exam)\n\n          -  Age > 18\n\n          -  Estimated life expectancy > 12 weeks\n\n          -  No prior radiation therapy or chemotherapy within 1 month of study enrollment\n\n          -  ANC > 1000, PLT>75,000, Serum creatinine<2.5 mg/dL, Bilirubin <1.5 x upper limits of\n             normal (ULN)\n\n          -  Diabetes must be controlled prior to PET-CT scanning (blood glucose <200 mg/dL)\n\n          -  Ability to provide written informed consent\n\n        Exclusion Criteria:\n\n          -  Evidence of distant metastasis on upright chest x-ray (CXR), computed tomography (CT)\n             or other staging studies\n\n          -  Patients in their reproductive age group should use an effective method of birth\n             control.  Patients who are breast-feeding, or have a positive pregnancy test will be\n             excluded from the study\n\n          -  Any co-morbidity or condition of sufficient severity to limit full compliance with\n             the protocol per assessment by the investigator\n\n          -  Concurrent serious infection\n\n          -  History of known hypersensitivity to cetuximab, docetaxel or similar agents"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "92", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 30, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02057107", 
            "org_study_id": "11-112"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "SBRT + Cetuximab + Docetaxel followed by Cetuximab + Docetaxel", 
                    "SBRT + Cetuximab followed by Cetuximab"
                ], 
                "description": "8.8-10 Gy per fraction (total: 44-50 Gy)", 
                "intervention_name": "SBRT", 
                "intervention_type": "Radiation", 
                "other_name": [
                    "Radiosurgery", 
                    "Stereotactic radiosurgery", 
                    "CyberKnife", 
                    "True Beam", 
                    "Trilogy"
                ]
            }, 
            {
                "arm_group_label": [
                    "SBRT + Cetuximab + Docetaxel followed by Cetuximab + Docetaxel", 
                    "SBRT + Cetuximab followed by Cetuximab"
                ], 
                "description": "Day -7 (One week prior to commencement of stereotactic radiosurgery):\nCetuximab, 400 mg/m2\nDays 0 and 8 (The 1st and 2nd week of radiosurgery):\nCetuximab, 250 mg/m2 Cetuximab, 250 mg/m2 will be given weekly ( following radiosurgery)", 
                "intervention_name": "Cetuximab", 
                "intervention_type": "Drug", 
                "other_name": "Erbitux"
            }, 
            {
                "arm_group_label": "SBRT + Cetuximab + Docetaxel followed by Cetuximab + Docetaxel", 
                "description": "Days 0 and 8 (The 1st and 2nd week of radiosurgery) Docetaxel, 25 mg/m2 Docetaxel, 25 mg/m2 will be given weekly (following radiosurgery)", 
                "intervention_name": "Docetaxel", 
                "intervention_type": "Drug", 
                "other_name": "Taxotere"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Docetaxel", 
                "Cetuximab"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 4, 2014", 
        "location": {
            "contact": {
                "email": "holevakd@upmc.edu", 
                "last_name": "Karen D Holeva, BS", 
                "phone": "412-623-1275"
            }, 
            "contact_backup": {
                "email": "herond2@upmc.edu", 
                "last_name": "Dwight E Heron, MD", 
                "phone": "412-623-6720"
            }, 
            "facility": {
                "address": {
                    "city": "Pittsburgh", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "15232"
                }, 
                "name": "UPMC Shadyside Radiation Oncology"
            }, 
            "investigator": [
                {
                    "last_name": "David A Clump, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Steven Burton, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Brian J Karlovits, DO", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Robert Ferris, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "James Ohr, DO", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Julie Bauman, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Dwight E Heron, MD", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN)", 
        "overall_contact": {
            "email": "holevakd@upmc.edu", 
            "last_name": "Karen D Holeva, BS", 
            "phone": "412-623-1275"
        }, 
        "overall_contact_backup": {
            "email": "herond2@upmc.edu", 
            "last_name": "Dwight E Heron, MD", 
            "phone": "412-623-6720"
        }, 
        "overall_official": {
            "affiliation": "University of Pittsburgh", 
            "last_name": "Dwight E Heron, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Evaluated by PET/CT or CT", 
            "measure": "Locoregional progression-free survival (PFS) of previously-irradiated patients with SCCHN treated with SBRT, cetuximab, and docetaxel", 
            "safety_issue": "No", 
            "time_frame": "1 Year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02057107"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Determined by patient follow up CTCAE criteria", 
            "measure": "Acute and late toxicities associated with the above therapy", 
            "safety_issue": "Yes", 
            "time_frame": "3 years"
        }, 
        "source": "University of Pittsburgh", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Pittsburgh", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}